{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:04:50Z","timestamp":1790064290375,"version":"4.0.1"},"publisher-location":"Cham","reference-count":81,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030357269","type":"print"},{"value":"9783030357276","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-35727-6_9","type":"book-chapter","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T16:07:08Z","timestamp":1581005228000},"page":"127-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tumor Microenvironment Conditioning by Abortive Lytic Replication of Oncogenic \u03b3-Herpesviruses"],"prefix":"10.1007","author":[{"given":"Christian","family":"M\u00fcnz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"9_CR1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-pathol-012513-104656","volume":"9","author":"E Cesarman","year":"2014","unstructured":"Cesarman E (2014) Gammaherpesviruses and lymphoproliferative disorders. Annu Rev Pathol 9:349\u2013372","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"9_CR2","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood-2018-11-852442","volume":"133","author":"E Oksenhendler","year":"2019","unstructured":"Oksenhendler E, Boutboul D, Galicier L (2019) Kaposi sarcoma-associated herpesvirus\/human herpesvirus 8-associated lymphoproliferative disorders. Blood 133(11):1186\u20131190","journal-title":"Blood"},{"key":"9_CR3","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","volume":"1","author":"JL Kutok","year":"2006","unstructured":"Kutok JL, Wang F (2006) Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 1:375\u2013404","journal-title":"Annu Rev Pathol"},{"issue":"1732","key":"9_CR4","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0275","volume":"372","author":"G Mariggio","year":"2017","unstructured":"Mariggio G, Koch S, Schulz TF (2017) Kaposi sarcoma herpesvirus pathogenesis. Philos Trans R Soc Lond B Biol Sci 372(1732):20160275","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"9_CR5","doi-asserted-by":"crossref","unstructured":"M\u00fcnz C (2019) Latency and lytic replication in Epstein Barr virus associated oncogenesis. Nat Rev Microbiol 17(11):691\u2013700","DOI":"10.1038\/s41579-019-0249-7"},{"issue":"14","key":"9_CR6","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1128\/JVI.00443-13","volume":"87","author":"SM Tugizov","year":"2013","unstructured":"Tugizov SM, Herrera R, Palefsky JM (2013) Epstein-Barr virus transcytosis through polarized oral epithelial cells. J Virol 87(14):8179\u20138194","journal-title":"J Virol"},{"issue":"4","key":"9_CR7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007039","volume":"14","author":"A Murer","year":"2018","unstructured":"Murer A, McHugh D, Caduff N, Kalchschmidt JS, Barros MH, Zbinden A et al (2018) EBV persistence without its EBNA3A and 3C oncogenes in vivo. PLoS Pathog 14(4):e1007039","journal-title":"PLoS Pathog"},{"issue":"3","key":"9_CR8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","volume":"9","author":"GJ Babcock","year":"1998","unstructured":"Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998) EBV persistence in memory B cells in vivo. Immunity 9(3):395\u2013404","journal-title":"Immunity"},{"issue":"15","key":"9_CR9","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood-2012-03-415620","volume":"121","author":"SH Sin","year":"2013","unstructured":"Sin SH, Dittmer DP (2013) Viral latency locus augments B-cell response in vivo to induce chronic marginal zone enlargement, plasma cell hyperplasia, and lymphoma. Blood 121(15):2952\u20132963","journal-title":"Blood"},{"key":"9_CR10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.coviro.2016.09.001","volume":"20","author":"J Totonchy","year":"2016","unstructured":"Totonchy J, Cesarman E (2016) Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy? Curr Opin Virol 20:71\u201377","journal-title":"Curr Opin Virol"},{"issue":"6","key":"9_CR11","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.V96.6.2069","volume":"96","author":"E Oksenhendler","year":"2000","unstructured":"Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP et al (2000) High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 96(6):2069\u20132073","journal-title":"Blood"},{"issue":"6","key":"9_CR12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.20160120","volume":"213","author":"JS Kalchschmidt","year":"2016","unstructured":"Kalchschmidt JS, Bashford-Rogers R, Paschos K, Gillman AC, Styles CT, Kellam P et al (2016) Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med 213(6):921\u2013928","journal-title":"J Exp Med"},{"issue":"4","key":"9_CR13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006967","volume":"14","author":"J Totonchy","year":"2018","unstructured":"Totonchy J, Osborn JM, Chadburn A, Nabiee R, Argueta L, Mikita G et al (2018) KSHV induces immunoglobulin rearrangements in mature B lymphocytes. PLoS Pathog 14(4):e1006967","journal-title":"PLoS Pathog"},{"issue":"4","key":"9_CR14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1074-7613(00)00049-2","volume":"13","author":"JG Babcock","year":"2000","unstructured":"Babcock JG, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13(4):497\u2013506","journal-title":"Immunity"},{"issue":"2","key":"9_CR15","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1128\/JVI.79.2.1296-1307.2005","volume":"79","author":"LL Laichalk","year":"2005","unstructured":"Laichalk LL, Thorley-Lawson DA (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79(2):1296\u20131307","journal-title":"J Virol"},{"issue":"3","key":"9_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm830","volume":"9","author":"SM Tugizov","year":"2003","unstructured":"Tugizov SM, Berline JW, Palefsky JM (2003) Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med 9(3):307\u2013314","journal-title":"Nat Med"},{"key":"9_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.med.56.082103.104727","volume":"56","author":"S Gottschalk","year":"2005","unstructured":"Gottschalk S, Rooney CM, Heslop HE (2005) Post-transplant lymphoproliferative disorders. Annu Rev Med 56:29\u201344","journal-title":"Annu Rev Med"},{"issue":"17","key":"9_CR18","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1158\/1078-0432.CCR-08-2979","volume":"15","author":"KW Ong","year":"2009","unstructured":"Ong KW, Teo M, Lee V, Ong D, Lee A, Tan CS et al (2009) Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin Cancer Res 15(17):5350\u20135358","journal-title":"Clin Cancer Res"},{"issue":"2","key":"9_CR19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semcancer.2012.02.004","volume":"22","author":"SW Tsao","year":"2012","unstructured":"Tsao SW, Tsang CM, Pang PS, Zhang G, Chen H, Lo KW (2012) The biology of EBV infection in human epithelial cells. Semin Cancer Biol 22(2):137\u2013143","journal-title":"Semin Cancer Biol"},{"key":"9_CR20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2042-4280-2-8","volume":"2","author":"CP Fox","year":"2011","unstructured":"Fox CP, Shannon-Lowe C, Rowe M (2011) Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae 2:8","journal-title":"Herpesviridae"},{"issue":"12","key":"9_CR21","volume":"14","author":"TM Rose","year":"2018","unstructured":"Rose TM, Bruce AG, Barcy S, Fitzgibbon M, Matsumoto LR, Ikoma M et al (2018) Quantitative RNAseq analysis of Ugandan KS tumors reveals KSHV gene expression dominated by transcription from the LTd downstream latency promoter. PLoS Pathog 14(12):e1007441","journal-title":"PLoS Pathog"},{"issue":"1","key":"9_CR22","volume":"14","author":"FY Tso","year":"2018","unstructured":"Tso FY, Kossenkov AV, Lidenge SJ, Ngalamika O, Ngowi JR, Mwaiselage J et\u00a0al (2018) RNA-Seq of Kaposi\u2019s sarcoma reveals alterations in glucose and lipid metabolism. PLoS Pathog 14(1):e1006844","journal-title":"PLoS Pathog"},{"issue":"3","key":"9_CR23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0002-9440(10)64940-1","volume":"156","author":"C Parravicini","year":"2000","unstructured":"Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS et al (2000) Differential viral protein expression in Kaposi\u2019s sarcoma-associated herpesvirus-infected diseases: Kaposi\u2019s sarcoma, primary effusion lymphoma, and multicentric Castleman\u2019s disease. Am J Pathol 156(3):743\u2013749","journal-title":"Am J Pathol"},{"issue":"2","key":"9_CR24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/JVI.75.2.891-902.2001","volume":"75","author":"RG Jenner","year":"2001","unstructured":"Jenner RG, Alba MM, Boshoff C, Kellam P (2001) Kaposi\u2019s sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol 75(2):891\u2013902","journal-title":"J Virol"},{"issue":"1","key":"9_CR25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chom.2017.06.009","volume":"22","author":"D McHugh","year":"2017","unstructured":"McHugh D, Caduff N, Barros MHM, R\u00e4mer P, Raykova A, Murer A et al (2017) Persistent KSHV infection increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene expression. Cell Host Microbe 22(1):61\u201373","journal-title":"Cell Host Microbe"},{"issue":"10","key":"9_CR26","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrc2888","volume":"10","author":"EA Mesri","year":"2010","unstructured":"Mesri EA, Cesarman E, Boshoff C (2010) Kaposi\u2019s sarcoma and its associated herpesvirus. Nat Rev Cancer 10(10):707\u2013719","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"9_CR27","volume":"11","author":"SH Sin","year":"2015","unstructured":"Sin SH, Kim Y, Eason A, Dittmer DP (2015) KSHV latency locus cooperates with Myc to drive lymphoma in mice. PLoS Pathog 11(9):e1005135","journal-title":"PLoS Pathog"},{"issue":"3","key":"9_CR28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1172\/JCI44417","volume":"121","author":"G Ballon","year":"2011","unstructured":"Ballon G, Chen K, Perez R, Tam W, Cesarman E (2011) Kaposi sarcoma herpesvirus (KSHV) vFLIP oncoprotein induces B cell transdifferentiation and tumorigenesis in mice. J Clin Invest 121(3):1141\u20131153","journal-title":"J Clin Invest"},{"issue":"12","key":"9_CR29","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/j.1460-2075.1996.tb00674.x","volume":"15","author":"JB Wilson","year":"1996","unstructured":"Wilson JB, Bell JL, Levine AJ (1996) Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J 15(12):3117\u20133126","journal-title":"EMBO J"},{"issue":"20","key":"9_CR30","doi-asserted-by":"crossref","first-page":"11963","DOI":"10.1073\/pnas.95.20.11963","volume":"95","author":"W Kulwichit","year":"1998","unstructured":"Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N (1998) Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci U S A 95(20):11963\u201311968","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR31","first-page":"35","volume":"391","author":"B Kempkes","year":"2015","unstructured":"Kempkes B, Ling PD (2015) EBNA2 and its coactivator EBNA-LP. Curr Top Microbiol Immunol 391:35\u201359","journal-title":"Curr Top Microbiol Immunol"},{"key":"9_CR32","first-page":"119","volume":"391","author":"A Kieser","year":"2015","unstructured":"Kieser A, Sterz KR (2015) The latent membrane protein 1 (LMP1). Curr Top Microbiol Immunol 391:119\u2013149","journal-title":"Curr Top Microbiol Immunol"},{"issue":"12","key":"9_CR33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nrmicro2015","volume":"6","author":"DA Thorley-Lawson","year":"2008","unstructured":"Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt\u2019s lymphoma. Nat Rev Microbiol 6(12):913\u2013924","journal-title":"Nat Rev Microbiol"},{"key":"9_CR34","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1038\/s41388-018-0147-x","volume":"37","author":"S AlQarni","year":"2018","unstructured":"AlQarni S, Al-Sheikh Y, Campbell D, Drotar M, Hannigan A, Boyle S et al (2018) Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2. Oncogene 37:3998","journal-title":"Oncogene"},{"issue":"34","key":"9_CR35","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1038\/sj.onc.1210299","volume":"26","author":"D Bubman","year":"2007","unstructured":"Bubman D, Guasparri I, Cesarman E (2007) Deregulation of c-Myc in primary effusion lymphoma by Kaposi\u2019s sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 26(34):4979\u20134986","journal-title":"Oncogene"},{"issue":"19","key":"9_CR36","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.00804-07","volume":"81","author":"J Liu","year":"2007","unstructured":"Liu J, Martin HJ, Liao G, Hayward SD (2007) The Kaposi\u2019s sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol 81(19):10451\u201310459","journal-title":"J Virol"},{"issue":"42","key":"9_CR37","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1038\/sj.onc.1202976","volume":"18","author":"PM Chaudhary","year":"1999","unstructured":"Chaudhary PM, Jasmin A, Eby MT, Hood L (1999) Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 18(42):5738\u20135746","journal-title":"Oncogene"},{"issue":"52","key":"9_CR38","doi-asserted-by":"crossref","first-page":"52437","DOI":"10.1074\/jbc.M304199200","volume":"278","author":"Q Sun","year":"2003","unstructured":"Sun Q, Zachariah S, Chaudhary PM (2003) The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J Biol Chem 278(52):52437\u201352445","journal-title":"J Biol Chem"},{"issue":"15","key":"9_CR39","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1093\/nar\/gks391","volume":"40","author":"K Paschos","year":"2012","unstructured":"Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40(15):7233\u20137246","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"9_CR40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003187","volume":"9","author":"L Skalska","year":"2013","unstructured":"Skalska L, White RE, Parker GA, Turro E, Sinclair AJ, Paschos K et al (2013) Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog 9(2):e1003187","journal-title":"PLoS Pathog"},{"key":"9_CR41","first-page":"151","volume":"391","author":"O Cen","year":"2015","unstructured":"Cen O, Longnecker R (2015) Latent membrane protein 2 (LMP2). Curr Top Microbiol Immunol 391:151\u2013180","journal-title":"Curr Top Microbiol Immunol"},{"issue":"12","key":"9_CR42","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/sj.onc.1205360","volume":"21","author":"G Platt","year":"2002","unstructured":"Platt G, Carbone A, Mittnacht S (2002) p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma. Oncogene 21(12):1823\u20131831","journal-title":"Oncogene"},{"issue":"10","key":"9_CR43","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2002-10-3090","volume":"101","author":"U Klein","year":"2003","unstructured":"Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R et al (2003) Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 101(10):4115\u20134121","journal-title":"Blood"},{"issue":"18","key":"9_CR44","doi-asserted-by":"crossref","first-page":"10399","DOI":"10.1073\/pnas.1630810100","volume":"100","author":"RG Jenner","year":"2003","unstructured":"Jenner RG, Maillard K, Cattini N, Weiss RA, Boshoff C, Wooster R et al (2003) Kaposi\u2019s sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci U S A 100(18):10399\u201310404","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell PJ (2019) Epstein-Barr virus and cancer. Annu Rev Pathol 14:29\u201353","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"9_CR46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0060-9","volume":"5","author":"E Cesarman","year":"2019","unstructured":"Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D (2019) Kaposi sarcoma. Nat Rev Dis Primers 5(1):9","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"9_CR47","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI58092","volume":"122","author":"RE White","year":"2012","unstructured":"White RE, Ramer PC, Naresh KN, Meixlsperger S, Pinaud L, Rooney C et al (2012) EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 122(4):1487\u20131502","journal-title":"J Clin Invest"},{"issue":"20","key":"9_CR48","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","volume":"125","author":"A Arvey","year":"2015","unstructured":"Arvey A, Ojesina AI, Pedamallu CS, Ballon G, Jung J, Duke F et al (2015) The tumor virus landscape of AIDS-related lymphomas. Blood 125(20):e14\u2013e22","journal-title":"Blood"},{"key":"9_CR49","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43653","volume":"8","author":"A Walens","year":"2019","unstructured":"Walens A, DiMarco AV, Lupo R, Kroger BR, Damrauer JS, Alvarez JV (2019) CCL5 promotes breast cancer recurrence through macrophage recruitment in residual tumors. Elife 8:e43653","journal-title":"Elife"},{"issue":"24","key":"9_CR50","doi-asserted-by":"crossref","first-page":"17794","DOI":"10.1074\/jbc.M702001200","volume":"282","author":"HR Luttichau","year":"2007","unstructured":"Luttichau HR, Johnsen AH, Jurlander J, Rosenkilde MM, Schwartz TW (2007) Kaposi sarcoma-associated herpes virus targets the lymphotactin receptor with both a broad spectrum antagonist vCCL2 and a highly selective and potent agonist vCCL3. J Biol Chem 282(24):17794\u201317805","journal-title":"J Biol Chem"},{"issue":"7","key":"9_CR51","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.V87.7.2918.bloodjournal8772918","volume":"87","author":"H Herbst","year":"1996","unstructured":"Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H et al (1996) Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin\u2019s disease. Blood 87(7):2918\u20132929","journal-title":"Blood"},{"issue":"4","key":"9_CR52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1008301602785","volume":"10","author":"AH Sarris","year":"1999","unstructured":"Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C et al (1999) Interleukin-10 levels are often elevated in serum of adults with Hodgkin\u2019s disease and are associated with inferior failure-free survival. Ann Oncol 10(4):433\u2013440","journal-title":"Ann Oncol"},{"issue":"16","key":"9_CR53","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","volume":"133","author":"K Lurain","year":"2019","unstructured":"Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Goncalves PH et al (2019) Viral, immunologic, and clinical features of primary effusion lymphoma. Blood 133(16):1753\u20131761","journal-title":"Blood"},{"issue":"11","key":"9_CR54","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood.V92.11.4256","volume":"92","author":"MT Bejarano","year":"1998","unstructured":"Bejarano MT, Masucci MG (1998) Interleukin-10 abrogates the inhibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 92(11):4256\u20134262","journal-title":"Blood"},{"issue":"5","key":"9_CR55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002704","volume":"8","author":"S Jochum","year":"2012","unstructured":"Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R (2012) The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination. PLoS Pathog 8(5):e1002704","journal-title":"PLoS Pathog"},{"issue":"3","key":"9_CR56","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0046-8177(93)90034-E","volume":"24","author":"SM Hsu","year":"1993","unstructured":"Hsu SM, Lin J, Xie SS, Hsu PL, Rich S (1993) Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin\u2019s Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin\u2019s disease. Hum Pathol 24(3):249\u2013255","journal-title":"Hum Pathol"},{"issue":"2","key":"9_CR57","volume":"7","author":"GW Tan","year":"2018","unstructured":"Tan GW, Visser L, Tan LP, van den Berg A, Diepstra A (2018) The microenvironment in Epstein-Barr virus-associated malignancies. Pathogens 7(2):E40","journal-title":"Pathogens"},{"issue":"42","key":"9_CR58","doi-asserted-by":"crossref","first-page":"E6467","DOI":"10.1073\/pnas.1605884113","volume":"113","author":"M Albanese","year":"2016","unstructured":"Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J et\u00a0al (2016) Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci U S A 113(42):E6467\u2013E6E75","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"9_CR59","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01941-18","volume":"10","author":"A Murer","year":"2019","unstructured":"Murer A, Ruhl J, Zbinden A, Capaul R, Hammerschmidt W, Chijioke O et al (2019) MicroRNAs of Epstein-Barr virus attenuate T-cell-mediated immune control in vivo. MBio 10(1):e01941-18","journal-title":"MBio"},{"issue":"5671","key":"9_CR60","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.1096781","volume":"304","author":"S Pfeffer","year":"2004","unstructured":"Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J et\u00a0al (2004) Identification of virus-encoded microRNAs. Science 304(5671):734\u2013736","journal-title":"Science"},{"issue":"5","key":"9_CR61","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1158\/0008-5472.CAN-07-5126","volume":"68","author":"T Xia","year":"2008","unstructured":"Xia T, O\u2019Hara A, Araujo I, Barreto J, Carvalho E, Sapucaia JB et al (2008) EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 68(5):1436\u20131442","journal-title":"Cancer Res"},{"issue":"14","key":"9_CR62","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1073\/pnas.140129797","volume":"97","author":"L Coscoy","year":"2000","unstructured":"Coscoy L, Ganem D (2000) Kaposi\u2019s sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci U S A 97(14):8051\u20138056","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9_CR63","first-page":"355","volume":"391","author":"ME Ressing","year":"2015","unstructured":"Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ (2015) Immune evasion by Epstein-Barr virus. Curr Top Microbiol Immunol 391:355\u2013381","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"9_CR64","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/bloodadvances.2018025536","volume":"3","author":"C Gujer","year":"2019","unstructured":"Gujer C, Murer A, Muller A, Vanoaica D, Sutter K, Jacque E et al (2019) Plasmacytoid dendritic cells respond to Epstein-Barr virus infection with a distinct type I interferon subtype profile. Blood Adv 3(7):1129\u20131144","journal-title":"Blood Adv"},{"issue":"1","key":"9_CR65","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/JVI.01512-10","volume":"85","author":"SD Ma","year":"2011","unstructured":"Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y et al (2011) A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 85(1):165\u2013177","journal-title":"J Virol"},{"issue":"8","key":"9_CR66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004333","volume":"10","author":"O Antsiferova","year":"2014","unstructured":"Antsiferova O, M\u00fcller A, R\u00e4mer P, Chijioke O, Chatterjee B, Raykova A et al (2014) Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog 10(8):e1004333","journal-title":"PLoS Pathog"},{"issue":"7","key":"9_CR67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007179","volume":"14","author":"JA Bristol","year":"2018","unstructured":"Bristol JA, Djavadian R, Albright ER, Coleman CB, Ohashi M, Hayes M et al (2018) A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog 14(7):e1007179","journal-title":"PLoS Pathog"},{"issue":"22","key":"9_CR68","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01132-18","volume":"92","author":"S Correia","year":"2018","unstructured":"Correia S, Bridges R, Wegner F, Venturini C, Palser A, Middeldorp JM et al (2018) Sequence variation of Epstein-Barr virus: viral types, geography, codon usage, and diseases. J Virol 92(22):e01132-18","journal-title":"J Virol"},{"issue":"3","key":"9_CR69","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","volume":"4","author":"Y Okuno","year":"2019","unstructured":"Okuno Y, Murata T, Sato Y, Muramatsu H, Ito Y, Watanabe T et al (2019) Defective Epstein-Barr virus in chronic active infection and haematological malignancy. Nat Microbiol 4(3):404\u2013413","journal-title":"Nat Microbiol"},{"issue":"26","key":"9_CR70","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","volume":"117","author":"TS Uldrick","year":"2011","unstructured":"Uldrick TS, Polizzotto MN, Aleman K, O\u2019Mahony D, Wyvill KM, Wang V et al (2011) High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 117(26):6977\u20136986","journal-title":"Blood"},{"issue":"14","key":"9_CR71","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJM199904083401402","volume":"340","author":"DF Martin","year":"1999","unstructured":"Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340(14):1063\u20131070","journal-title":"N Engl J Med"},{"issue":"1","key":"9_CR72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00042560-199901010-00005","volume":"20","author":"R Robles","year":"1999","unstructured":"Robles R, Lugo D, Gee L, Jacobson MA (1999) Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi\u2019s sarcoma in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 20(1):34\u201338","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"1","key":"9_CR73","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hon.2445","volume":"36","author":"J Marquet","year":"2018","unstructured":"Marquet J, Velazquez-Kennedy K, Lopez S, Benito A, Blanchard MJ, Garcia-Vela JA (2018) Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy. Hematol Oncol 36(1):316\u2013319","journal-title":"Hematol Oncol"},{"issue":"3","key":"9_CR74","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","volume":"104","author":"N Casagrande","year":"2019","unstructured":"Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D (2019) CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica 104(3):564\u2013575","journal-title":"Haematologica"},{"issue":"13","key":"9_CR75","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1200\/JCO.2011.39.6853","volume":"30","author":"TS Uldrick","year":"2012","unstructured":"Uldrick TS, Wyvill KM, Kumar P, O\u2019Mahony D, Bernstein W, Aleman K et al (2012) Phase II study of bevacizumab in patients with HIV-associated Kaposi\u2019s sarcoma receiving antiretroviral therapy. J Clin Oncol 30(13):1476\u20131483","journal-title":"J Clin Oncol"},{"key":"9_CR76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-med-070209-175325","volume":"62","author":"J Laubach","year":"2011","unstructured":"Laubach J, Richardson P, Anderson K (2011) Multiple myeloma. Annu Rev Med 62:249\u2013264","journal-title":"Annu Rev Med"},{"issue":"5","key":"9_CR77","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3816\/CLM.2008.n.042","volume":"8","author":"T Siddiqi","year":"2008","unstructured":"Siddiqi T, Joyce RM (2008) A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma 8(5):300\u2013304","journal-title":"Clin Lymphoma Myeloma"},{"issue":"7","key":"9_CR78","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/apm.12029","volume":"121","author":"G Muzes","year":"2013","unstructured":"Muzes G, Sipos F, Csomor J, Sreter L (2013) Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman\u2019s disease of plasma cell type nonresponsive to rituximab-CVP therapy. APMIS 121(7):668\u2013674","journal-title":"APMIS"},{"key":"9_CR79","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-7-10","volume":"7","author":"A Nagao","year":"2014","unstructured":"Nagao A, Nakazawa S, Hanabusa H (2014) Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol 7:10","journal-title":"J Hematol Oncol"},{"issue":"5","key":"9_CR80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004068","volume":"10","author":"S Linnerbauer","year":"2014","unstructured":"Linnerbauer S, Behrends U, Adhikary D, Witter K, Bornkamm GW, Mautner J (2014) Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders. PLoS Pathog 10(5):e1004068","journal-title":"PLoS Pathog"},{"issue":"12","key":"9_CR81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007464","volume":"14","author":"DG van Zyl","year":"2018","unstructured":"van Zyl DG, Tsai MH, Shumilov A, Schneidt V, Poirey R, Schlehe B et al (2018) Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog 14(12):e1007464","journal-title":"PLoS Pathog"}],"container-title":["Advances in Experimental Medicine and Biology","Tumor Microenvironment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-35727-6_9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T15:23:28Z","timestamp":1609773808000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-030-35727-6_9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030357269","9783030357276"],"references-count":81,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-35727-6_9","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"7 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}